Trial intelligence / Profile preview

Voriconazole ± anidulafungin for primary therapy of invasive aspergillosis in pediatric patients

2010-021231-14Phase 3Terminated

Sponsor: Pfizer
Start: Nov 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
Countries: 1

Overview

Phase 3, randomised trial in invasive aspergillosis (IA) and aspergillosis comparing Voriconazole monotherapy with Voriconazole + anidulafungin combination (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2010; status: terminated.

Drugs

voriconazoleanidulafungin

Conditions

invasive aspergillosis (IA)aspergillosis

Beyond the preview

Go deeper on 2010-021231-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-021231-14.